Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 13/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.42 |
| ▸ | TSHR | P16473 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 6/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985343 | 0.94 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL30746419 | 0.94 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL26985134 | 0.93 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL30746372 | 0.93 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL30746673 | 0.91 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL26984891 | 0.91 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL31401688 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL30746539 | 0.83 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL30746514 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| SCHEMBL26984959 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-120129678-A | Mitogen-activated protein kinase (MEK) inhibitors | 耐斯泰德医疗公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | CYP1A2 877/4885CYP3A4 2298/4885CYP2D6 468/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | CYP1A2 1418/4885CYP3A4 1724/4885CYP2D6 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.